News & Press Releases
BioFluidica Will Exhibit at AACR 2023, Orlando, FL April 14-19th – Come See Us!
The American Association for Cancer Research, AACR, will hold their annual meeting in Orlando, FL, April 14-19th. BioFluidica will be exhibiting their Products and Services. The meeting brings people together [Read More...]
HER2+ Breast Cancer Pilot Study
February 9, 2023 Blood was drawn from 16 breast cancer patients and enriched for Circulating Tumor Cells (CTCs) using LiquidScan. Isolated cells were analyzed for HER2 positivity [Read More...]
BioFluidica Exhibits and Presents at PMWC 2023 in Santa Clara, CA
February 9, 2023 BioFluidica attended the Precision Medicine World Conference (PMWC) 2023 on January 25-27th. Every year PMWC gathers top researchers and medical professionals from all over [Read More...]
Exciting News – Offering Free Pilot to One Lucky Scientist at the SABCS Conference
December 1, 2022 BioFluidica is excited about next week’s San Antonio Breast Cancer Symposium (SABCS). We want to share our enthusiasm with you about LiquidScan exosome and [Read More...]
BioFluidica Exhibits at AMP 2022 in Phoenix, Arizona
November 1 - 5 BioFluidica attended the Association for Molecular Pathology (AMP) 2022 Annual Meeting and Expo this week, showcasing their LiquidScan technology. AMP is the leading [Read More...]
Microfluidic affinity selection of active SARS-CoV-2 virus particles
September 28, 2022 The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causing coronavirus disease 2019 (COVID-19) has been found to be highly infectious resulting in the need [Read More...]
Liquid Biopsies Take Center Stage at 2022 ASCO Annual Meeting
By Jamie Reno, June 15, 2022 BioFluidica presented its LiquidScan, a microfluidic chip that searches a blood sample for rare biomarkers such as CTCs (circulating tumor cells), cell-free [Read More...]
BioFluidica Attends and Exhibits at ASCO Annual Meeting
June 3 - 7, 2022 BioFluidica attended the ASCO Annual Meeting, exhibiting at Booth 21160 and presenting a poster abstract about the results of a patient sample [Read More...]
BioFluidica to Introduce Next-Generation Biomarker Isolation Platform
April 5, 2022 SAN DIEGO - Biofluidica today announced they will be introducing their new biomarker isolation platform, LiquidScan™, at the annual AACR Conference on April 10-13 [Read More...]
BioFluidica Nabs $6M in Funding
By LabPulse.com staff writers, February 10, 2022 February 10, 2022 -- Biotechnology company BioFluidica raised more than $6 million in a recent round of financing. The San Diego-based [Read More...]
Ultrasound in Obstetrics and Gynecology
By Jiri Sonek, January 17, 2021. M.U. is a 32-year-old G2 P1 Caucasian female, who presented at 13 weeks’ gestation by LMP for first trimester combined screening. [Read More...]
BioFluidica Presents at AACR 2019
April 1, 2019. BioFluidica presented at the AACR Conference in Atlanta, GA, April 2019 the following abstracts, "A Non-invasive Diagnostics to Detect Circulating Leukemic Cells in Blood. [Read More...]
Market Intel: Liquid Biopsy-Ready For Prime Time?
MedTech Insight | Bob Kronemyer, March 12, 2019 San Diego, California-based BioFluidica Inc. developed the Liquid Scan microfluidic chip that can both monitor and detect circulating tumor [Read More...]
BioFluidica Presents at Molecular Med TRI-CON
March 10, 2019 BioFluidica presented at the Molecular Med Tri-Conference in San Francisco, CA, March 2019 the following abstracts, "Detection of CTCs from Whole Blood of Lung [Read More...]
BioFluidica CoFounder and CTO, Stephen Soper, on Facebook Live: Bench to Bedside.
The University of Kansas Cancer Center, January 20, 2019 Tune in February 20, 2019 as KU Cancer Center director Roy Jensen, MD, will host Steven Soper, PhD, KU [Read More...]
BioFluidica Applying Liquid Biopsy to Detect Leukemia While Reducing Biopsies
genomeweb | By John Gilmore, January 17, 2019 NEW YORK (GenomeWeb) – Fresh off being awarded several grants by the National Institutes of Health, startup BioFluidica has [Read More...]
In Promise of True Liquid Biopsy for Cancer, Chip Company BioFluidica® Awarded $1.7 Million by National Cancer Institute/National Institutes of Health for Clinical Trial in Children with Acute Lymphoblastic Leukemia
PR Newswire, January 10, 2019 SAN DIEGO /PRNewswire/ -- BioFluidica, a privately held cancer diagnostics company, has been awarded an SBIR Phase II National Institutes of Health grant [Read More...]
San Diego Blood Chip Maker BioFluidica Awarded Two NIH/NCI Grants for Isolation of Cell-Free DNA and Exosomes on Its Single Liquid Biopsy Platform
PR Newswire, January 07, 2019 SAN DIEGO /PRNewswire/ -- BioFluidica, a privately held cancer diagnostics company, has been awarded two separate SBIR Phase I NIH grants, the first [Read More...]
BioFluidica presents at the Prenatal Diagnostics Conference
November, 2018 BioFluidica presented at the Prenatal Diagnostics Conference in Boston, MA, November 2018 the following abstract titled "A Microfluidic Platform to Capture & Detect Trophoblastic Fetal [Read More...]
BioFluidica turns to blood for accurate, inexpensive cancer tests
San Diego Union Tribune | By Bradley J. Fikes, August 31, 2018 Blood is hard to beat for detecting disease. This liquid tissue circulates throughout the body, picking up [Read More...]
In Promise of True Liquid Biopsy for Cancer, BioFluidica® Launches Human Trial for Rapid Detection of Minimal Residual Disease in Acute Myeloid Leukemia from Peripheral Blood Using high through-put automation and programmable Microfluidic Chips
PR Newswire, May 19, 2018 SAN DIEGO /PRNewswire/ -- BioFluidica, a privately held cancer diagnostics company, today announced the continuation of a highly successful small patient study [Read More...]